Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06876688 | Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma | recruiting | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT05595447 | Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma | recruiting | Phase 2 / Phase 3 | 20 | Hospital Regional de Alta Especialidad del BajioOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06667973 | Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia | not yet recruiting | Phase 2 | 80 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT06871007 | Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma | enrolling by invitation | Phase 1 / Phase 2 | 22 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT02781883 | Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML | recruiting | Phase 2 | 108 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06863584 | SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial | recruiting | Phase 2 | 41 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06861348 | Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT(ZJU-HSCT-INO) | not yet recruiting | Phase 2 | 23 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT05487170 | A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | recruiting | Phase 1 / Phase 2 | 32 | Ranok Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 2 | Mar 4, 2025 | clinicaltrials |
| NCT04980885 | A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 68 | AkesoINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06848569 | Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study | recruiting | Phase 2 | 73 | Sun Yat-sen UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04271644 | BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | recruiting | Phase 1 / Phase 2 | 80 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04776330 | a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | recruiting | Phase 1 / Phase 2 | 80 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06299462 | PTCy and ATG for MSD and MUD Transplants | recruiting | Phase 1 / Phase 2 | 50 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06743945 | POLA-R-CHP in the First-line Treatment of Transformed DLBCL | recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06845241 | Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 68 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06453902 | TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients | recruiting | Phase 2 | 40 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06827899 | Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML | recruiting | Phase 2 | 66 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT05603884 | VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | Phase 2 | 66 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06151080 | Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL | recruiting | Phase 2 | 38 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06151106 | Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma | recruiting | Phase 2 | 33 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06158386 | Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma | recruiting | Phase 2 | 33 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06158399 | AZA Combined With RCHOP in P53-mutated DLBCL. | recruiting | Phase 2 | 52 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06158412 | All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma | recruiting | Phase 2 | 25 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT05870995 | Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia | recruiting | Phase 2 | 100 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT05881265 | Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia | recruiting | Phase 2 | 30 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06557161 | A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL | recruiting | Phase 2 | 170 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06559345 | A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL | recruiting | Phase 2 | 276 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06564493 | A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL | recruiting | Phase 2 | 170 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06564545 | A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL | recruiting | Phase 2 | 276 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06824883 | Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma | recruiting | Phase 2 | 49 | Peking Union Medical College HospitalOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06826118 | Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06093841 | Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL | active not recruiting | Phase 2 | 46 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06642792 | A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 280 | AkesoINDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05597345 | Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma | recruiting | Phase 2 | 15 | University of RochesterOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04586478 | Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma | recruiting | Phase 2 | 60 | Juventas Cell Therapy Ltd.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06668792 | An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma(FLAMMINGO) | recruiting | Phase 2 | 100 | BiocadINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06799676 | A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma | not yet recruiting | Phase 1 / Phase 2 | 42 | Fuling ZhouOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05601726 | First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients(ODYSSEY) | recruiting | Phase 1 / Phase 2 | 36 | Advanced BioDesignINDUSTRY | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06783478 | NK Cell Infusion for Remission Consolidation in AML: A Phase II Trial(NKLMA) | not yet recruiting | Phase 2 | 98 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06783790 | Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06754540 | Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention. | not yet recruiting | Phase 2 | 51 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jan 17, 2025 | clinicaltrials |
| NCT04782687 | Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 73 | US Oncology ResearchINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06115135 | A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 39 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06777264 | Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1(JUVENTAS-ALL05) | not yet recruiting | Phase 2 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 0 | Jan 15, 2025 | clinicaltrials |
| NCT05263583 | Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma | active not recruiting | Phase 2 | 14 | Cothera Bioscience, IncINDUSTRY | 2 | Jan 14, 2025 | clinicaltrials |
| NCT05281809 | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 30 | John ListerOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05885464 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | active not recruiting | Phase 1 / Phase 2 | 5 | Beam Therapeutics Inc.INDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06179524 | CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL | recruiting | Phase 2 | 100 | Beijing Yongtai Ruike Biotechnology Company LtdINDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06765915 | Avapritinib Maintenance for AML With KIT Mutations | not yet recruiting | Phase 2 | 47 | Ruijin HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06765928 | Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT | not yet recruiting | Phase 2 | 73 | Ruijin HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 14, 2025source: clinicaltrials